|Bid price||155.00||Open price||157.50|
|Ask price||160.00||Prev close||157.50|
Register now for FREE live Summit Therapeutics share prices, Summit Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Therapeutics Level 2 Data, indepth research tools and investor commentary for Summit Therapeutics (SUMM) and other London Stock Exchange equities.
Register now for FREE Summit Therapeutics share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00BN40HZ01|
|Activites||Summit Therapeutics plc (formerly Summit Corporation plc, formerly VASTox plc) is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.||Index||n/a|
|Latest Share Price (p)||157.50||Net Gearing (%)||-49.30|
|Market Capitalisation (£m)||97.36||Gross Gearing (%)||15.72|
|Shares in issue (m)||61.82||Debt Ratio||3.37|
|P/E Ratio||-3.84||Debt-to-Equity Ratio||0.19|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.19|
|Dividend Yield (%)||0.00||Price to book value||3.25|
|Dividend cover (x)||0.00||ROCE (%)||-92.13|
|Earning per share (p)||-41.00||EPS Growth (%)||-41.38|
|52 week high / low||260.00 / 82.50||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|26/07/2013||PLAC||Dr Frank Armstrong||CH||50,000|
Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 AND OPERATIONAL PROGRESS Oxford, UK, 15 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and...
Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 ON 15 DECEMBER 2016 Oxford, UK, 13 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company...
Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ENROLS PATIENTS IN THE UNITED STATES INTO PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 16 November 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development...
Register now for FREE Summit Therapeutics company news
http://www.summitplc.com/ Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...
OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll after...
Register now for FREE Summit Therapeutics share price discussions